CHRS
What one share of Coherus Oncology holds
Biological Products, (No Diagnostic Substances)
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers.
Coherus Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.39 |
|---|---|
| Profit | −$1.00 |
| Cash and investments | $0.68 |
| Book value | $0.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$3.04 | $0.16 | −$6.18 | — | $0.45 |
| 2017 | — | −$4.48 | $0.09 | −$3.86 | — | $0.51 |
| 2018 | — | −$3.22 | $0.01 | −$2.46 | — | −$0.56 |
| 2019 | $4.87 | $1.23 | $0.02 | $0.36 | — | $1.50 |
| 2020 | $5.70 | $1.58 | $0.09 | $1.76 | — | $3.87 |
| 2021 | $4.33 | −$3.81 | $0.02 | −$0.51 | — | $1.27 |
| 2022 | $2.72 | −$3.76 | $0.03 | −$3.13 | — | −$1.74 |
| 2023 | $2.73 | −$2.53 | $0.00 | −$1.86 | — | −$1.72 |
| 2024 | $0.23 | $0.25 | — | −$0.18 | — | −$1.14 |
| 2025 | $0.36 | $1.43 | — | −$1.18 | — | $0.50 |